Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...
GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM ...
The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results